XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.3
LICENSE, COLLABORATION AND OTHER REVENUE (Tables)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenues Recognized from License, Collaboration and Other Significant Agreements
The Company recognized the following revenue from its license, collaboration and other revenue agreements (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
EntityDescription2024202320242023
Medice
License and royalties related to the sale of Vafseo in the EU
$29 $— $29 $10,000 
MTPCLicense and Product Supply of Vafseo in Japan525 487 2,106 5,165 
JT and Torii License and royalties related to the sale of Riona in Japan1,282 1,441 3,738 3,969 
Otsuka Terminated U.S. and International Agreements— — — 2,225 
Total license and other revenue $1,836 $1,928 $5,873 $21,359 
Changes in Contract Assets and Liabilities
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Nine Months Ended September 30, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:    
Accounts receivable(1)
$3,333 $5,873 $(7,381)$1,825 
Contract liability:
Deferred revenue(2)
$43,296 $— $(43,296)$— 
Nine Months Ended September 30, 2023
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$1,901 $1,426 $(2,847)$480 
Prepaid expenses and other current assets$781 $— $(781)$— 
Contract liabilities:
Deferred revenue$47,034 $— $(3,738)$43,296 
(1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia which are included in the accompanying unaudited condensed consolidated balance sheets as of September 30, 2024 and 2023.
(2) See Note 8, Liability Related to Settlement Royalties, Working Capital Fund Liability and Liability Related to Sale of Future Royalties, for further information.
Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
The Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended September 30,Nine Months Ended September 30,
Revenue Recognized in the Period:2024202320242023
Deferred revenue — beginning of the period$— $— $— $3,738